Navigation Links
Progen Expands Drug Development Pipeline Through Acquisition of CellGate
Date:2/4/2008

ake CGC11047 through a rigorous pre- and clinical assessment in the coming 18 months before determining a future mid-stage clinical development program for this product candidate. Complementing this first generation clinical candidate is a series of next- generation pre-clinical compounds that have shown strong anti-tumor activity in animal cancer models. These compounds represent potential new drug candidates for Progen that target both the polyamine as well as epigenetic pathways. In addition, CellGate has active research collaborations with Johns Hopkins and Wayne State Universities with the goal of generating new compounds with strong activity against the epigenetic targets LSD-1 and HDAC.

Terms of the Agreement

Under the terms of the agreement, the up-front purchase price will comprise the issue of 756,199 Progen shares having a value of approximately $US1.5 million and the assumption by Progen of CellGate net liabilities up to $US1.0 million.

The shares will be issued as follows: 604,959 Progen shares on closing, 75,620 Progen shares on the date 6 months after closing and 75,620 Progen shares on the date 12 months after closing. The 6 and 12 month deferred issues of shares are subject to there having been no material breaches of warranties and representations given by CellGate. In the event CellGate's net liabilities at closing are less than $1.0 million Progen will issue additional shares for the difference but the total number of shares to be issued (including the 604,959 shares of up-front consideration) will in no event exceed 957,464 Progen shares. These additional shares will be issued approximately 45 days after closing. Any remaining difference will be paid in cash at closing.

Additional milestone payments of up to $US19.5 million, payable to the CellGate shareholders in Progen shares (to the extent permissible without shareholder approval) and/or cash, are to be made upon the achievement of certain clinical and regulatory m
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Progentix Orthobiology B.V. Closes Series A Financing Round
2. Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD)
3. Progeniq Joins Microsoft in Bio IT Alliance
4. Progen Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
5. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
6. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
7. PPD Expands Global Central Lab Services into China
8. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
9. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
10. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
11. Symmetry Medical Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters ... a high-end machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or ... design that even NIST used them for their SRM-2031 series going back for many ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... highly-regarded by Fortune 500 companies and professional service industries alike-- typically known for ... make clients laugh, honor a good cause and break from their day jobs. ...
(Date:7/3/2015)... Forskere kan søke ... Science", som finner sted i ... på  http://www.openinnovationinscience.at , og søknadsperioden varer frem ... to største utfordringene innen helsevitenskapen er mangelen ... og kompleksiteten av nåværende forskningsresultater, i følge ...
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... the cuvette they needed. As expected, this was a daunting and tiring process looking ... because they were not able to navigate the complex catalog structure. , Now thanks to ...
Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2
... the Cost of Genome Analysis to $100 In ... Routine Medical Care-PHILADELPHIA, Feb. 24 BioNanomatrix, Inc., ... analysis platforms for biomedical research, molecular diagnostics and ... genome analysis technology, along with founder and chief ...
... Gene Network Sciences, Inc. (GNS) today announced that it ... Officer of Stromedix, Inc. and former Executive Vice President ... Directors. Dr. Gilman has been Founder and Chief ... was previously Executive Vice President, Research at Biogen Idec. ...
... PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense ... threats, announced today that results from a Phase ... for Valortim(R) were presented at the 7th Annual ... held in Baltimore, MD, February 22-25, 2009. David ...
Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Gene Network Sciences Announces Michael Gilman as Board Member 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 3PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 4PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 5PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 6PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 7
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... the leading cause of blindness in western society, say experts ... a new eye instrument, they have launched a study to ... strength could also explain why the 77-year-old sailor has no ... sweetcorn, kale and broccoli are rich in a chemical called ...
... virtually any other type of therapy, has given rise ... also great concerns regarding health risks. Since the Deutsche ... in 1995, this field of research has developed enormously. ... as well as the risks of gene therapy. The ...
... to accurately distinguish benign from malignant breast lesions. ... and harmless lesions in nearly all of the ... the annual meeting of the Radiological Society of ... imaging has been found to have high specificity,?said ...
Cached Biology News:Why Popeye only has eyes for spinach 2Development of gene therapy 2Elasticity imaging identifies cancers and reduces breast biopsies 2
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Biology Products: